2025-07-19 - Analysis Report
Okay, here's a report based on the data you provided, including numerical summaries, comparative analysis, and a final overall assessment.

**Report: TG Therapeutics Inc (TGTX)**

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO):**

*   **TGTX Cumulative Return:** 68.38%
*   **VOO Cumulative Return:** 96.72%
*   **Absolute Performance Difference:** -28.35%
*   **Relative Performance Deviation:** -26.4 (Range: Max 401.1, Min -110.5, Relative Deviation: 16.4)

**Analysis of Alpha, Beta, CAGR, and MDD:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
|------------|---------|--------|----------|--------|--------|
| 2015-2017  | -6.0%  | 56.5%  | -35.0%   | -0.1   | 1.3    |
| 2016-2018  | -8.0%  | 58.6%  | -26.0%   | 0.0    | 0.7    |
| 2017-2019  | 74.0%  | 58.6%  | 44.0%   | 0.0    | 1.8    |
| 2018-2020  | 402.0% | 58.6%  | 382.0%  | -0.4   | 8.3    |
| 2019-2021  | 125.0% | 63.5%  | 76.0%   | -0.5   | 3.0    |
| 2020-2022  | -76.0% | 70.4%  | -78.0%   | -0.6   | 1.9    |
| 2021-2023  | -350.0%| 70.4%  | -368.0%  | -0.8   | 2.7    |
| 2022-2024  | 71.0%  | 73.1%  | 45.0%   | -0.9   | 4.8    |
| 2023-2025  | 75.0%  | 73.1%  | 27.0%   | 0.4    | 6.0    |

**Analysis:** The provided data reveals a high level of volatility and risk associated with TGTX. The CAGR varies widely, with some periods showing substantial gains (e.g., 2018-2020) and others significant losses (e.g., 2021-2023). The Maximum Drawdown (MDD) is consistently high, indicating substantial potential for loss. Alpha values are also highly variable, reflecting periods of both significant outperformance and underperformance relative to the S&P 500. The Beta values fluctuate, suggesting that the stock's volatility is not consistently correlated with the overall market.

**2. Recent Price Action:**

*   **Current Price:** $37.91
*   **Previous Close:** $39.19
*   **Change:** -3.27%
*   **5-Day Moving Average:** $38.56
*   **20-Day Moving Average:** $37.27
*   **60-Day Moving Average:** $37.19

**Analysis:** The stock price decreased by 3.27% and is currently below the 5-day moving average but above the 20-day and 60-day moving averages. This suggests a short-term downward trend, but the price is still relatively stable when considering a longer-term view.

**3. Technical Indicators & Outlook:**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 55.19 (Neutral)
*   **PPO:** 0.477 (Positive, but close to zero)
*   **Hybrid Signal:** Cash_0%_Buy 90% of cash (1 shares - Safe)
*   **20-Day Relative Deviation Change:** 1.9 (Positive - Short-term Increase)
*   **Expected Return:** -236.3%

**Analysis:**

*   The MRI indicates a low-risk market environment.
*   The RSI is neutral, suggesting neither overbought nor oversold conditions.
*   The PPO is slightly positive, indicating a weak upward trend.
*   The hybrid signal suggests a bullish stance, recommending buying 90% of cash.
*   The change in relative deviation suggests a recent short-term increase.
*   The dramatically negative expected return (-236.3%) is a significant concern. If the model is correct, it means if you buy now and hold for the long term, you would expect to lose more money than the S&P 500.

**Impact of Price Change:** The significant price drop from the previous close warrants attention. Such a drop could be attributed to various factors, including negative news, broader market downturns, or profit-taking.

**4. Recent News & Significant Events:**

*   **[2025-07-17]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-15]:** Analyst discussions on recent performance and outlook.
*   **[2025-07-16]:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **[2025-07-18]:** Market experts highlighting risks and opportunities.

**Analysis:** Recent news suggests that TGTX has been subject to significant volatility, driven by market events and news.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2024-05-06 | -0.07 | 0.06 B$   |
| 2025-05-09 | -0.07 | 0.06 B$   |

**Analysis:** The earnings data shows fluctuating EPS and revenue figures. There's been a recent increase in revenue, but profitabilty are inconsistent, suggesting that revenue and earnings are not stable

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |
| 2024-03-31 | $0.06B  | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-03-31 | $0.24B  | 2.13%   |
| 2024-12-31 | $0.22B  | 10.49%   |
| 2024-09-30 | $0.19B  | 2.02%    |
| 2024-06-30 | $0.18B  | 3.87%    |
| 2024-03-31 | $0.16B  | -6.69%   |

**Analysis:** Revenue has generally increased over the past year, but profit margins have been relatively stable. Equity has also grown, but ROE has fluctuated significantly, suggesting inconsistent profitability and efficiency in utilizing equity.

**7. Overall Assessment:**

TG Therapeutics Inc. (TGTX) presents a mixed picture.

*   **Negatives:** The stock has underperformed the S&P 500 over the period examined, and the MDD is very high. The dramatically negative expected return is a red flag.
*   **Positives:** Revenue is increasing, and recent technical indicators are mixed, with some suggesting short-term potential. The market risk indicator is low.
*   **Overall:** The company is high-risk, high-reward. It is critical to monitor the news closely. The recent price drop and negative expected return raise significant concerns and should prompt further investigation.
